News | December 31, 2023
Alkem completes sale of St. Louis manufacturing facility for US$ 7.96 million
The unit’s contribution to the company's revenue US$3.85 million in the last fiscal year
The unit’s contribution to the company's revenue US$3.85 million in the last fiscal year
The company has received Form 483 with three observations
The countrywide initiative aims to spread awareness, educate the public & ensure that no one is left behind in the fight against respiratory diseases
The initiative will focus on advocating for cleaner air
Education on Inhalation Therapy & Conducting Nationwide Awareness Camps, Alkem Breathe Initiative Addresses the Alarming Increase in Respiratory Diseases in India
Biosergen AB is developing BSG005 for the treatment of severe and difficult-to-treat invasive fungal diseases
Introduces a line-up of brands targeting key therapeutic categories for its ophthalmology segment launc
Approximately 60 to 78% of individuals diagnosed with Asthma also have concurrent Allergic Rhinitis
The company has reported total income of Rs. 2971.27 crores during the period ended March 31, 2023
Alkem has submitted a detailed corrective and preventive action (CAPA) plan to the regulator within the stipulated timelines.
Subscribe To Our Newsletter & Stay Updated
